Rabbit Polyclonal Anti-CD22 antibody (STJ98831)

$99.00$319.00

Reactivity: Human, Mouse, Rat
Applications: WB, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Rabbit Polyclonal Anti-CD22 antibody (STJ98831)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, ELISA

Recommended dilution: WB 1:500-2000; ELISA 1:5000-20001

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for Anti-CD22 antibody.

Alternative names:

Check alternative names for the antibody

Expand

|OSRC antibody|Osteosarcoma antibody|p105-Rb antibody|P105RB antibody|PP105 antibody|pp110 antibody|PPP1R130 antibody|pRb antibody|Prepro retinoblastoma associated protein antibody|Protein phosphatase 1 regulatory subunit 130 antibody|Rb antibody|RB_HUMAN antibody|RB1 antibody|RB1 gene antibody|Retinoblastoma 1 antibody|Retinoblastoma suspectibility protein antibody|Retinoblastoma-associated protein antibody|Phospho anti-Rb (S780) antibody (ab47763)
SCBT cat No: sc-74562|

Name

Anti-CD22 antibody

Catalogue No.

STJ98831

Reactivity

Human, Mouse, Rat

Specificity

Anti-CD22 antibody detects endogenous levels of Rb (Acetyl-K873/K874). It doesn’t reacte with total protein.

Immunogen

Synthesized Acetyl peptide derived from Human Rb at AA range: K873/872.

Host

Rabbit

Applications

WB, ELISA

Recommended dilution

WB 1:500-2000; ELISA 1:5000-20001

Clonality

Polyclonal

Conjugation

Unconjugated

Isotype

IgG

Formulation

Anti-CD22 antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration

1 mg/ml

Purification

Anti-CD22 antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

OSRC antibody, Osteosarcoma antibody, p105-Rb antibody, P105RB antibody, PP105 antibody, pp110 antibody, PPP1R130 antibody, pRb antibody, Prepro retinoblastoma associated protein antibody, Protein phosphatase 1 regulatory subunit 130 antibody, Rb antibody, RB_HUMAN antibody, RB1 antibody, RB1 gene antibody, Retinoblastoma 1 antibody, Retinoblastoma suspectibility protein antibody, Retinoblastoma-associated protein antibody

Database links

UniProt/Swiss-Prot:P06400

Protein function

Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 ‘Lys-20’ trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1’s activity. .

Protein tissue specificity

Expressed in the retina.

Involvement in disease

Childhood cancer retinoblastoma (RB) [MIM:180200]: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20’000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil (‘cat eye’) is investigated. . Note=The disease is caused by mutations affecting the gene represented in this entry.; Bladder cancer (BLC) [MIM:109800]: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Osteogenic sarcoma (OSRC) [MIM:259500]: A sarcoma originating in bone-forming cells, affecting the ends of long bones. Note=The disease is caused by mutations affecting the gene represented in this entry.

Protein sequence and domain

Belongs to the retinoblastoma protein (RB) family. The Pocket domain binds to the threonine-phosphorylated domain C, thereby preventing interaction with heterodimeric E2F/DP transcription factor complexes.

Protein post-translational modifications

Phosphorylated by CDK6 and CDK4, and subsequently by CDK2 at Ser-567 in G1, thereby releasing E2F1 which is then able to activate cell growth. Dephosphorylated at the late M phase. SV40 large T antigen, HPV E7 and adenovirus E1A bind to the underphosphorylated, active form of pRb. Phosphorylation at Thr-821 and Thr-826 promotes interaction between the C-terminal domain C and the Pocket domain, and thereby inhibits interactions with heterodimeric E2F/DP transcription factor complexes. Dephosphorylated at Ser-795 by calcineruin upon calcium stimulation. CDK3/cyclin-C-mediated phosphorylation at Ser-807 and Ser-811 is required for G0-G1 transition. Phosphorylated by CDK1 and CDK2 upon TGFB1-mediated apoptosis (By similarity). .; N-terminus is methylated by METTL11A/NTM1 (By similarity). Monomethylation at Lys-810 by SMYD2 enhances phosphorylation at Ser-807 and Ser-811, and promotes cell cycle progression. Monomethylation at Lys-860 by SMYD2 promotes interaction with L3MBTL1. .; Acetylation at Lys-873 and Lys-874 regulates subcellular localization, at least during keratinocytes differentiation. .

Protein cellular localization

Nucleus .

Note

AntibodyPlus can customize Anti-CD22 antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:



Welcome to AntibodyPlus!